| abstract |
A bispecific Fabs-In-Tandem immunoglobulin (FIT-Ig) -binding protein that simultaneously binds to both EGFR and PD-L1 is disclosed. Such bispecific EGFR / PD-L1 FIT-Ig binding proteins are efficiently expressed and useful for blocking EGFR signaling, blocking PD-L1 signaling, and treating cancer. [Selection diagram] Fig. 1 |